Compare GSK plc (GSK) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs H2O America — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while H2O America trades at $58.54 (market cap $2.43B). The key difference: GSK plc is far larger — about 37.8× H2O America's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and H2O America for 40 Days on average.
| GSK | HTO | |
|---|---|---|
Market Cap | $91.88B | $2.43B |
Volume | 7,730,529 | 593,883 |
Sector | Health | Utilities |
52-Week High | $61.18 | $65.43 |
52-Week Low | $43.24 | $44.44 |
Typical Hold Time | 93 Days | 40 Days |
Enterprise Value | $111.88B | $4.22B |
Dividend Yield | 3.9% | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
HTO trades at $58.70, up 1.24% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains strong profitability with 12.91% net margins and recently completed the Quadvest acquisition through its Texas subsidiary. Analyst consensus remains strongly bullish with 83% buy ratings and a $66.50 price target, representing 13% upside potential from current levels.
The outlook appears favorable given the strategic acquisitions and Dividend King status, though execution risks from recent equity dilution and negative cash flow from investing activities warrant monitoring. The stock offers value with reasonable P/E of 20.45 and consistent earnings beats, supported by institutional accumulation including BlackRock's significant position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
